MedPath

In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise

Not Applicable
Active, not recruiting
Conditions
Interventional
Interventions
Dietary Supplement: BCAA Supplement
Dietary Supplement: Collagen Supplement
Dietary Supplement: Di-Leucine Supplement
Registration Number
NCT05754125
Lead Sponsor
University of Toronto
Brief Summary

This study seeks to investigate the anabolic potential of a dileucine-enriched essential amino acid (EAA) formulation compared with a branched chain amino acid (BCAA) alternative and a collagen beverage on muscle protein anabolism and catabolism following a bout of resistance exercise training. To do this, investigators will employ a novel 'breath test' method developed in our laboratory as well as blood and urine sampling. The results of this study will allow us to better understand the anabolic potential of dileucine which could have implications for people engaging in regular resistance training (such as athletes) as well as people that need to preserve muscle mass (older people who are susceptible to anabolic resistance and sarcopenia, or muscle wasting).

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Trained individuals currently performing structured exercise (e.g., running, weightlifting, team-sport activity) at least 2 days per week for the previous 3 months
Exclusion Criteria
  • Inability to perform physical activity as determined by the PAR-Q
  • Inability to adhere to protocol guidelines (e.g., alcohol, habitual diet)
  • Regular tobacco use
  • Illicit drug use (e.g., growth hormone, testosterone, etc.)
  • Diagnosed medical condition under the care of a physician (e.g. type 2 diabetes)
  • Inability to abstain from supplements (e.g. protein, creatine, HMB, BCAA, phosphatidic acid, etc.) at least three weeks before the trial
  • Individuals on any medications known to affect protein metabolism (e.g., corticosteroids, non-steroidal anti-inflammatories, or prescription-strength acne medications)
  • Participants that are amenorrheic (females only)
  • On medications that may interfere with protein metabolism (e.g. anti-inflammatory drugs, hormone therapy)
  • Regular tobacco use (e.g. daily use of oral or inhaled tobacco)
  • Illicit drug use (e.g. growth hormone, testosterone, etc.)
  • Inability to comply with the study protocol as judged by the investigators

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
BCAA SupplementBCAA SupplementParticipants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
Collagen SupplementCollagen SupplementParticipants will consume a amino acid supplement containing collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
Di-Leucine supplementDi-Leucine SupplementParticipants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
Primary Outcome Measures
NameTimeMethod
Whole-Body Protein Synthesis6 hours

Investigators will measure the enrichment of \[13CO2\] in the breath by isotope ratio mass spectrometry (IRMS) in atom percent excess (APE). The measurement of carbon dioxide production (VCO2) and stable isotope tracer enrichment in the breath allows for the assessment of the rate at which amino acids are used for energy (i.e., oxidized), rather than for protein synthesis (i.e., retained in the body) by calculating the fraction of expired CO2 that contains 13C. Leucine retention (umol/kg) will then be calculated from the difference between the known amount of leucine provided (ingested) and leucine oxidation (as determined from 13CO2 breath enrichment).

Secondary Outcome Measures
NameTimeMethod
Murine Cell-Based Experiments (ex-vivo experiments) - Protein Synthesis60 minutes

Investigators will use human serum obtained from fasted and fed timepoints (15, 30, 45 and 60 minutes following beverage consumption) to condition cell culture media (20% volume). To determine the effects of using fasted and/or fed 'human-conditioned' culture media on cell protein synthesis, puromycin incorporation (measure of protein synthesis) will be measured via western blot.

Murine Cell-Based Experiments (ex-vivo experiments) -hypertrophy60 minutes

Investigators will use human serum obtained from fasted and fed timepoints (15, 30, 45 and 60 minutes following beverage consumption) to condition cell culture media (20% volume). To determine the effects of using fasted and/or fed 'human-conditioned' culture media on cell growth, myotube diameter (hypertrophy) will be measured via microscopy following short term (4 hours) and long-term (24 hour) incubation in the human conditioned culture media.

Urinary Measures (Muscle Protein Breakdown)6 hours

Investigators will measure urinary 3-methylhistidine (3MH) as an indirect marker of muscle protein breakdown over the course of the trial (6 hours) through pooled urine collection vs baseline urine.

Murine Cell-Based Experiments (ex-vivo experiments) - mTORC1 Signalling60 minutes

Investigators will use human serum obtained from fasted and fed timepoints (15, 30, 45 and 60 minutes following beverage consumption) to condition cell culture media (20% volume). To determine the effects of using fasted and/or fed 'human-conditioned' culture media on cell anabolic signalling mTORC1 signalling will be measured via western blot.

Trial Locations

Locations (1)

Goldring Centre for High Performance Sport at the University of Toronto

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath